NeuroPace Announces New Leadership Appointments
Key Developers Join NeuroPace
NeuroPace, a medical device company focused on improving the lives of individuals with epilepsy, has made significant moves in its leadership team. Brett Wingeier, a former key developer of the RNS System, has been appointed as the new Vice President of Research and Development. This is a strategic move that showcases NeuroPace’s commitment to innovation and advancement in the field of epilepsy treatment.
Marketing Expertise Added
In addition to Wingeier’s appointment, Katie Keller, who previously served as the head of commercial marketing for Boston Scientific’s DBS franchise, has been named as the new Vice President of Marketing at NeuroPace. Keller’s extensive experience in marketing within the medical device industry will undoubtedly bring a fresh perspective to NeuroPace’s marketing strategies.
Driving Growth and Innovation
These appointments come at a crucial time for NeuroPace, as the company continues to focus on developing cutting-edge technologies to help individuals with epilepsy manage their condition more effectively. Wingeier and Keller’s combined expertise will undoubtedly drive growth and innovation within the company, ultimately benefiting those living with epilepsy.
Implications for Individuals
For individuals living with epilepsy, these appointments signal promising advancements in treatment options and technologies that may potentially improve their quality of life. With a strong team in place, NeuroPace is poised to continue making strides in the field of epilepsy management.
Global Impact
On a larger scale, NeuroPace’s new leadership appointments have the potential to impact the world by setting new standards for epilepsy treatment and management. By bringing together top talent in research and development as well as marketing, NeuroPace is positioned to make a significant mark on the global healthcare landscape.
Conclusion
NeuroPace’s decision to appoint Brett Wingeier and Katie Keller to key leadership positions is a strategic move that highlights the company’s commitment to advancement and innovation in the field of epilepsy treatment. With a focus on growth and development, NeuroPace is well-positioned to make a positive impact on individuals living with epilepsy and the global healthcare community as a whole.
